#SNDA
🚨 $SNDA
Ribar Brandon (President & CEO) reported special transactions (Non-P/S).
SEC Filing: SNDA
Click to view the official SEC document.
www.sec.gov
November 17, 2026 at 11:52 PM
🚨 $SNDA
Cober Timothy (SVP & Chief Accounting Officer) reported special transactions (Non-P/S).
SEC Filing: SNDA
Click to view the official SEC document.
www.sec.gov
November 17, 2026 at 11:51 PM
An sNDA seeking the approval of selinexor plus ruxolitinib for patients with myelofibrosis is officially under @fda.gov review #mpnsm #oncology

Read more: www.onclive.com/view/fda-acc...
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis | OncLive
The FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.
www.onclive.com
November 17, 2026 at 6:23 PM
🟢 #$CYTK — Regulatory Approval
FDA Approves sNDA Adding MAPLE-HCM Data to MYQORZO Label
FDA approved the sNDA updating the U.S. Prescribing Information for MYQORZO (aficamten) to include Phase 3 MAPLE-HCM data comparing aficamten with metoprolol. Approval came …

https://biostock.app/symbols/CYTK
November 16, 2026 at 10:34 AM
Latest company news, November 17: $KPTI FDA accepts the XPOVIO + ruxolitinib sNDA in myelofibrosis, PDUFA June 28, 2027. Karyopharm remains in Chapter 11.

Full hub: https://www.merlintrader.com/karyopharm-therapeutics-stock-hub/?utm_source=bluesky&utm_medium=social&utm_campaign=kpti
November 17, 2026 at 4:40 PM
🟢 #$ARWR — Regulatory Designation
FDA STAR Pilot Program Entry - plozasiran sNDA in sHTG (6-month Priority Review)
FDA granted plozasiran entry in the Split Real Time Application Review (STAR) pilot program for the sHTG sNDA. Acceptance qualifies for a 6-month …

https://biostock.app/symbols/ARWR
November 12, 2026 at 9:10 PM
#$SNDA: Off-exchange shares (share of volume): Nov 11 107,695 (33.0%).
Dark pool volume Nov 11: 0.5x its normal level, 5-day trend rising.

Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days.

Full story at the link.
#darkpool #stocks #stockmarket
SNDA Technical Levels: Options Flow Mixed Between $32.15 and $33.99
SNDA at $33.71: support $32.15, resistance $33.99; the chart, options flow and dark pools are mixed.
globaltradersacademy.com
November 12, 2026 at 4:35 PM
Sonida Senior Living $SNDA: RBC Capital lowered its price target from $48.00 to $43.00 and maintained its Outperform rating.

https://fundspec.ai/s/SNDA/analysts
Compare any stock to its DCF fair value in seconds.
November 11, 2026 at 3:45 PM
Daiichi Sankyo Seeks Japan Approval for Trastuzumab Deruxtecan in HER2-Expressing Uterine Carcinosarcoma

https://www.byteseu.com/2516762/

Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for trastuzumab deruxtecan …
Daiichi Sankyo Seeks Japan Approval for Trastuzumab Deruxtecan in HER2-Expressing Uterine Carcinosarcoma - Bytes Europe
Daiichi Sankyo has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour and Welfare (MHLW) for trastuzumab deruxtecan in
www.byteseu.com
November 12, 2026 at 2:52 PM
Roivant's brepocitinib met all Phase 3 endpoints in non-infectious uveitis, reducing treatment failure risk by roughly 75% versus placebo. sNDA filing targeted for 2027.
Roivant's brepocitinib meets all Phase 3 endpoints in uveitis
Priovant plans a 2027 sNDA filing after brepocitinib cut treatment failure risk by roughly 75% versus placebo across two identical NIU trials.
thebiotechtimes.com
November 11, 2026 at 8:00 PM
🟢 #$IRD — Regulatory Approval
FDA Approves RYZUMVI (Phentolamine 0.75%) for Presbyopia - Milestone Payment from Viatris
Q3 2026 results 8-K reports FDA approval of the sNDA for phentolamine ophthalmic solution 0.75% (RYZUMVI) for presbyopia in adults, the second…

https://biostock.app/symbols/IRD
November 10, 2026 at 12:21 PM
📣 @fda.gov acceptance: The sNDA for gedatolisib (Revtorpyk) + fulvestrant ± palbociclib in PIK3CA-mutated HR+/HER2– advanced breast cancer is under review, with a PDUFA date of June 25, 2027.

🔗 www.onclive.com/view/gedatol...

#bcsm #oncology
Gedatolisib sNDA Accepted by FDA for PIK3CA-Mutated, HR+, HER2– Advanced Breast Cancer | OncLive
The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.
www.onclive.com
November 9, 2026 at 8:55 PM
Priovant plans to file an sNDA for brepocitinib in non-infectious uveitis in the first half of calendar 2027. That is the timeline $ROIV put on its second quarter ended September 30, 2026, the first with LISRAYA net product revenue: $31.0 million.

#stocks #investing #earnings
November 9, 2026 at 1:00 PM
ServiceNow Developer & Administrator [REF SNDA-0129] at Zolon Tech Solutions Inc.
Zolon Tech Solutions Inc., seeks qualified IT professionals for the following positions: ServiceNow Developer & Administrator (#SNDA-0129): Develop, maintain, customize & enhance apps on ServiceNow platform; build workflows & service requests; prepare requirements & tech specs; develop code & build CI/CD pipelines; configure UI, workflows & APIs; install & configure network hardware, software & document assets in CMDB; automate tasks using scripting tools; troubleshoot servers, firewalls & switches; implement standard IT processes; & related duties. Job in Herndon, VA. Travel/relocation to various unanticipated client locations throughout the US may be required. Send resume referencing the job code# to sam.mallipeddi@zolontech.com. EOE. ----------------------------------------------------------------------------------- JOBS.NOW Note: To tap into these hidden job opportunities, it is crucial to adhere strictly to the application process outlined in each job ad. At JOBS.NOW, we ensure that every listing includes detailed employer instructions. Follow them precisely to be considered for these unique positions! The "Log Application" button simply allows you to log the application for your records - JOBS.NOW does not submit any applications to employers directly. Remember to still apply through the method indicated in the job ad (mail, email, or via link). Please note that JOBS.NOW is an independent website and does not post this listings on behalf of any employers nor do we receive any compensation for these listings. All listings are sourced via media or internet channels required by the PERM process.
www.jobs.now
November 9, 2026 at 6:09 AM
Senior living company shares quarterly earnings update

Sonida Senior Living held an earnings call to discuss results from its third quarter.

via Yahoo Finance
seniorliving.news/story/what-s...
November 9, 2026 at 4:49 AM
#CELC Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic…

https://www.stocktitan.net/news/CELC/celcuity-announces-fda-acceptance-of-s-nda-for-revtorpyktm-aqro7lxzfbcd.html?utm_source=stocktitan-bluesky&utm_medium=social
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Celcuity (Nasdaq: CELC) announced FDA acceptance of its supplemental application to expand REVTORPYK use to PIK3CA-mutant advanced breast cancer. The FDA set a June 25, 2027 target decision date. The proposed indication covers HR-positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA mutation after progression on or after at least one line of endocrine therapy in the metastatic setting.The application draws on the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial. REVTORPYK, or gedatolisib, received FDA approval on July 14, 2026, with fulvestrant, with or without palbociclib, for the corresponding population without a detected PIK3CA mutation. Celcuity said approval of the expansion would make REVTORPYK available as second-line therapy regardless of tumor PIK3CA status. The expanded indication remains under review.
www.stocktitan.net
November 9, 2026 at 1:30 PM
🚨 $SNDA
Attached hereto as Exhibit 99.2 is the investor presentation used in connection with the Company’s webcast.
SEC Filing: SNDA
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 12:32 PM
Sonida Senior Living $SNDA reported Q3 2026 EPS of -$0.72, missing the -$0.51 estimate by 41.2%. Revenue of $210.2M beat the $206.7M estimate by 1.7%.

https://fundspec.ai/s/SNDA/earnings
50+ fundamentals like ROIC and free cash flow yield, ranked against the whole market.
November 5, 2026 at 12:37 PM
📉 Asian stocks and dollar fall on US midterms.
📈 Zevra anticipates filing MIPLYFFA sNDA in Q1 2027.
⚖️ Indonesia regulator announces stock violations sanctions.
November 4, 2026 at 7:26 AM
💥 The @fda.gov has granted priority review to an sNDA for zanubrutinib plus rituximab in untreated mantle cell lymphoma, supported by phase 3 MANGROVE data

Full details ➡️: www.onclive.com/view/fda-gra...

#oncology #lymsm
FDA Grants Priority Review to Zanubrutinib Plus Rituximab for Previously Untreated MCL | OncLive
The FDA granted priority review to an sNDA for zanubrutinib plus rituximab in untreated mantle cell lymphoma.
www.onclive.com
November 4, 2026 at 3:34 PM
Cytokinetics' aficamten showed sustained exercise gains and manageable safety in fresh ACACIA-HCM data. The company is on track for a supplemental filing in Q4 for non-obstructive HCM. Full story:
Cytokinetics presents additional ACACIA-HCM data on aficamten in nHCM
New analyses from the ACACIA-HCM trial reinforce aficamten's exercise and safety profile in non-obstructive HCM ahead of a planned Q4 sNDA submission.
thebiotechtimes.com
November 2, 2026 at 2:01 PM